{
     "PMID": "25315194",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160105",
     "LR": "20170220",
     "IS": "1740-634X (Electronic) 0893-133X (Linking)",
     "VI": "40",
     "IP": "4",
     "DP": "2015 Mar",
     "TI": "Enhanced dopamine-dependent hippocampal plasticity after single MK-801 application.",
     "PG": "987-95",
     "LID": "10.1038/npp.2014.276 [doi]",
     "AB": "Dopaminergic hyperfunction and N-methyl-D-aspartate receptor (NMDAR) hypofunction have both been implicated in psychosis. Dopamine-releasing drugs and NMDAR antagonists replicate symptoms associated with psychosis in healthy humans and exacerbate symptoms in patients with schizophrenia. Though hippocampal dysfunction contributes to psychosis, the impact of NMDAR hypofunction on hippocampal plasticity remains poorly understood. Here, we used an NMDAR antagonist rodent model of psychosis to investigate hippocampal long-term potentiation (LTP). We found that single systemic NMDAR antagonism results in a region-specific, presynaptic LTP at hippocampal CA1-subiculum synapses that is induced by activation of D1/D5 dopamine receptors and modulated by L-type voltage-gated Ca(2+) channels. Thereby, our findings may provide a cellular mechanism how NMDAR antagonism can lead to an enhanced hippocampal output causing activation of the hippocampus-ventral tegmental area-loop and overdrive of the dopamine system.",
     "FAU": [
          "Bartsch, Julia C",
          "Fidzinski, Pawel",
          "Huck, Jojanneke H J",
          "Hortnagl, Heide",
          "Kovacs, Richard",
          "Liotta, Agustin",
          "Priller, Josef",
          "Wozny, Christian",
          "Behr, Joachim"
     ],
     "AU": [
          "Bartsch JC",
          "Fidzinski P",
          "Huck JH",
          "Hortnagl H",
          "Kovacs R",
          "Liotta A",
          "Priller J",
          "Wozny C",
          "Behr J"
     ],
     "AD": "1] Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin, Berlin, Germany [2] Institute of Neurophysiology, Charite - Universitatsmedizin Berlin, Berlin, Germany. 1] Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin, Berlin, Germany [2] Institute of Neurophysiology, Charite - Universitatsmedizin Berlin, Berlin, Germany. Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charite - Universitatsmedizin Berlin, Berlin, Germany. Institute of Pharmacology and Toxicology, Charite - Universitatsmedizin Berlin, Berlin, Germany. Institute of Neurophysiology, Charite - Universitatsmedizin Berlin, Berlin, Germany. Institute of Neurophysiology, Charite - Universitatsmedizin Berlin, Berlin, Germany. 1] Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charite - Universitatsmedizin Berlin, Berlin, Germany [2] Cluster of Excellence NeuroCure, Charite - Universitatsmedizin Berlin, Berlin, Germany. Neuroscience Research Center, Charite - Universitatsmedizin Berlin, Berlin, Germany. 1] Department of Psychiatry and Psychotherapy, Charite - Universitatsmedizin Berlin, Berlin, Germany [2] Institute of Neurophysiology, Charite - Universitatsmedizin Berlin, Berlin, Germany [3] Department of Psychiatry and Psychotherapy, Ruppiner Kliniken, Neuruppin, Germany.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20141015",
     "PL": "England",
     "TA": "Neuropsychopharmacology",
     "JT": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
     "JID": "8904907",
     "RN": [
          "0 (Calcium Channel Blockers)",
          "0 (Enzyme Inhibitors)",
          "0 (Excitatory Amino Acid Antagonists)",
          "0 (GABA-A Receptor Antagonists)",
          "3KX376GY7L (Glutamic Acid)",
          "6LR8C1B66Q (Dizocilpine Maleate)",
          "EC 4.6.1.1 (Adenylyl Cyclases)",
          "I9ZF7L6G2L (Nifedipine)",
          "SY7Q814VUP (Calcium)",
          "VTD58H1Z2X (Dopamine)",
          "Y37615DVKC (Bicuculline)"
     ],
     "SB": "IM",
     "MH": [
          "Adenylyl Cyclases/metabolism",
          "Animals",
          "Bicuculline/pharmacology",
          "Calcium/metabolism",
          "Calcium Channel Blockers/pharmacology",
          "Dizocilpine Maleate/*pharmacology",
          "Dopamine/*metabolism",
          "Enzyme Inhibitors/pharmacology",
          "Excitatory Amino Acid Antagonists/*pharmacology",
          "GABA-A Receptor Antagonists/pharmacology",
          "Glutamic Acid/metabolism",
          "Hippocampus/*drug effects",
          "In Vitro Techniques",
          "Long-Term Potentiation/*drug effects",
          "Male",
          "Nifedipine/pharmacology",
          "Rats",
          "Rats, Wistar",
          "Signal Transduction/drug effects"
     ],
     "PMC": "PMC4330513",
     "EDAT": "2014/10/16 06:00",
     "MHDA": "2016/01/06 06:00",
     "CRDT": [
          "2014/10/16 06:00"
     ],
     "PHST": [
          "2014/03/04 00:00 [received]",
          "2014/09/17 00:00 [revised]",
          "2014/09/25 00:00 [accepted]",
          "2014/10/16 06:00 [entrez]",
          "2014/10/16 06:00 [pubmed]",
          "2016/01/06 06:00 [medline]"
     ],
     "AID": [
          "npp2014276 [pii]",
          "10.1038/npp.2014.276 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropsychopharmacology. 2015 Mar;40(4):987-95. doi: 10.1038/npp.2014.276. Epub 2014 Oct 15.",
     "term": "hippocampus"
}